Print this page
-
Open-Label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab with Pembrolizumab) in Combination with Concurrent Chemoradiotherapy followed by MK-7684A Versus Concurrent Chemoradiotherapy followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III NSCLC.
Protocol: 032205Principal Investigator:
- Salma Jabbour M.D. (Rutgers University)
Applicable Disease Sites: Lung -
Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And Intensification Clinical Trial Evaluation.
Protocol: 082201Principal Investigator:
- Lara Hathout MD (Rutgers University)
Applicable Disease Sites: Prostate -
A Phase II Study of Preoperative Pembrolizumab for Mismatch Repair Deficient, Epstein-Barr Virus Positive and/or PD-L1 Positive Gastric Cancer followed by Chemotherapy and Chemoradiation with Pembrolizumab.
Protocol: 071702Principal Investigator:
- Salma Jabbour M.D. (Rutgers University)
Applicable Disease Sites: Stomach -
Phase II Trial of Radium-223 Dichloride in Combination with Paclitaxel in Patients with Bone Metastatic Breast Cancer.
Protocol: 052001Principal Investigator:
- Salma Jabbour M.D. (Rutgers University)
Applicable Disease Sites: Breast -
A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies.
Protocol: 052002Principal Investigator:
- Salma Jabbour M.D. (Rutgers University)
Applicable Disease Sites: Liver
Any Site
Other Digestive Organ -
Randomized Phase III Trial Incorporating Abiraterone Acetate With Prednisone and Apalutamide and Advanced Imaging Into Salvage Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy.
Protocol: 082003Principal Investigator:
- Lara Hathout MD (Rutgers University)
Applicable Disease Sites: Prostate